Estimate of Relapse, EFS, and Survival According to Maintenance Treatment
. | No ATRA (n = 143) . | ATRA (n = 146) . | No CT (n = 145) . | CT (n = 144) . |
---|---|---|---|---|
Relapse | ||||
Events | 35 | 21 | 41 | 15 |
2-yr relapse | 25% | 13.5% | 27% | 11.5% |
Log rank | .024 | .0002 | ||
Stratified RR | .54 (.32-.92) | .33 (.18-.59) | ||
P = .024 | P = .0003 | |||
Stratified and adjusted4-150 RR | .62 (.36-1.10) | .31 (.17-.56) | ||
P = .10 | P = .0002 | |||
EFS | ||||
Events | 38 | 24 | 44 | 18 |
2-yr survival | 18% | 13% | 23% | 8% |
Log rank | .075 | .0006 | ||
Stratified RR | .66 (.39-1.10) | .41 (.23-.71) | ||
P = .10 | P = .0015 | |||
Stratified and adjusted4-150 RR | .74 (.42-1.27) | .41 (.24-.71) | ||
P = .27 | P = .0014 | |||
Survival | ||||
Deaths | 20 | 13 | 24 | 9 |
2-yr survival | 86% | 92% | 85% | 94% |
Log rank | .19 | P = .008 | ||
Stratified RR | .65 (.32-1.30) | .36 (.17-.78) | ||
P = .22 | P = .0097 | |||
Stratified and adjusted4-150 RR | .69 (.31-1.51) | .34 (.15-.79) | ||
P = .35 | P = .0117 |
. | No ATRA (n = 143) . | ATRA (n = 146) . | No CT (n = 145) . | CT (n = 144) . |
---|---|---|---|---|
Relapse | ||||
Events | 35 | 21 | 41 | 15 |
2-yr relapse | 25% | 13.5% | 27% | 11.5% |
Log rank | .024 | .0002 | ||
Stratified RR | .54 (.32-.92) | .33 (.18-.59) | ||
P = .024 | P = .0003 | |||
Stratified and adjusted4-150 RR | .62 (.36-1.10) | .31 (.17-.56) | ||
P = .10 | P = .0002 | |||
EFS | ||||
Events | 38 | 24 | 44 | 18 |
2-yr survival | 18% | 13% | 23% | 8% |
Log rank | .075 | .0006 | ||
Stratified RR | .66 (.39-1.10) | .41 (.23-.71) | ||
P = .10 | P = .0015 | |||
Stratified and adjusted4-150 RR | .74 (.42-1.27) | .41 (.24-.71) | ||
P = .27 | P = .0014 | |||
Survival | ||||
Deaths | 20 | 13 | 24 | 9 |
2-yr survival | 86% | 92% | 85% | 94% |
Log rank | .19 | P = .008 | ||
Stratified RR | .65 (.32-1.30) | .36 (.17-.78) | ||
P = .22 | P = .0097 | |||
Stratified and adjusted4-150 RR | .69 (.31-1.51) | .34 (.15-.79) | ||
P = .35 | P = .0117 |
Adjusted on induction assignment, age, gender, baseline WBC count, circulating blasts, platelet count, fibrinogen, and M3 subtype (classical M3v microganular M3).